Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial

Objectives Microalbuminuria is known as an independent predictor for stroke, myocardial infarction, and death. The purpose of the VALERIA trial was a comparison of the efficacy and safety of combination therapy of valsartan and lisinopril with valsartan and lisinopril high-dose monotherapy in patients with hypertension and microalbuminuria. Methods This was a randomized, double-blind, interventional, parallel-group study. After a washout/placebo- run-in phase of 3 weeks, 133 patients were randomized to treatment (1: 1:1) with either lisinopril 40 mg, valsartan 320 mg, or a combination of valsartan/lisinopril 320/20 mg for 30 weeks. Results At baseline, the urine albumin creatinine ratio was similar for the three treatment groups (geometric means, lisinopril 9.6 mg/mmol, valsartan 9.1 mg/mmol, and valsartan/lisinopril 9.5 mg/mmol). After 30 weeks of treatment, the geometric mean urine albumin creatinine ratio had decreased in all three groups by 41, 51, and 62% to 5.7 mg/mmol (lisinopril), 4.5 mg/mmol (valsartan), and 3.6 mg/mmol (valsartan/lisinopril). The decrease for valsartan/lisinopril was statistically significantly greater compared with lisinopril [adjusted ratio 60%, confidence interval (38–94%), P = 0.029]. Normalization of microalbuminuria was greatest with valsartan and valsartan/lisinopril (lisinopril 17%, valsartan 31%, and valsartan/lisinopril 38% of patients) and was statistically significant for lisinopril in contrast with valsartan/lisinopril (P = 0.034). Differences in blood pressure reduction between the groups were not statistically significant. All treatments were safe and well tolerated. Conclusion The combination of valsartan and lisinopril provided a significantly better reduction of urine albumin creatinine ratio and more than doubled the rate of patients with normalized urine albumin creatinine ratio compared with lisinopril alone. All treatments were safe and well tolerated.

[1]  S. Yusuf,et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[2]  G. Bakris,et al.  Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. , 2007, Kidney international.

[3]  K. Tuttle.  Albuminuria reduction: the holy grail for kidney protection. , 2007, Kidney international.

[4]  H. Parving,et al.  Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus , 2007, Journal of hypertension.

[5]  M. Weir.  Microalbuminuria and cardiovascular disease. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[6]  G. Fernández-Juárez,et al.  Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials. , 2006, Journal of the American Society of Nephrology : JASN.

[7]  O. Gedik,et al.  Effects of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and their combination on microalbuminuria in normotensive patients with type 2 diabetes , 2006, Advances in therapy.

[8]  R. Henning,et al.  Microalbuminuria and Endothelial Dysfunction: Emerging Targets for Primary Prevention of End-organ Damage , 2006, Journal of Cardiovascular Pharmacology.

[9]  Y. Altuntas,et al.  Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension. , 2006, Diabetes research and clinical practice.

[10]  H. Parving,et al.  Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. , 2005, Kidney international.

[11]  N. Wareham,et al.  What is the evidence that microalbuminuria is a predictor of cardiovascular disease events? , 2005, Current opinion in nephrology and hypertension.

[12]  M. Nieminen,et al.  Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study , 2005, Hypertension.

[13]  Hans L. Hillege,et al.  Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria , 2004, Circulation.

[14]  R. MacInnis,et al.  Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria , 2004, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[15]  H. Morita,et al.  Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. , 2003, Lancet.

[16]  H. Morita,et al.  RETRACTED: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial , 2003, The Lancet.

[17]  G. Leoncini,et al.  Microalbuminuria, cardiovascular, and renal risk in primary hypertension. , 2002, Journal of the American Society of Nephrology : JASN.

[18]  G. Viberti,et al.  Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus: A Blood Pressure–Independent Effect , 2002, Circulation.

[19]  O. Gedik,et al.  Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study , 2001, Acta Diabetologica.

[20]  S. Yusuf,et al.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. , 2001, JAMA.

[21]  D. Grobbee,et al.  Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity , 2001, Journal of internal medicine.

[22]  M. Cooper,et al.  Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study , 2000, BMJ : British Medical Journal.

[23]  J. García-Puig,et al.  Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. , 1996, Journal of human hypertension.

[24]  R. Garrick.  Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin–Angiotensin System on Proteinuria in Renal Disease , 2009 .

[25]  G. Kimura,et al.  [Microalbuminuria in hypertension]. , 2004, Nihon rinsho. Japanese journal of clinical medicine.